Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review

Patrick G McAleavey*, Gerard M Walls, Anthony J Chalmers

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)
96 Downloads (Pure)


Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide. The success of this combination has stimulated the search for other candidate drugs for concomitant use with RT in GBM. This review seeks to collate the current evidence for these agents and synthesize possible future directions for the field.

Original languageEnglish
Article numberCNS86
Number of pages13
JournalCNS Oncology
Issue number2
Early online date23 May 2022
Publication statusPublished - Jun 2022


  • Review
  • chemotherapy
  • glioblastoma
  • radiosensitizers
  • radiotherapy
  • trial design


Dive into the research topics of 'Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review'. Together they form a unique fingerprint.

Cite this